01 October 2005
Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia: Final report of the Polish Adult Leukemia Group (PALGCLL1).
Tadeusz Robak, Jerzy Z Błoński, Marek Kasznicki, Joanna Góra-Tybor, Anna Dmoszyńska, Maria Wojtaszko, Aleksander B Skotnicki, Wiesław Nowak, Andrzej Hellmann, Krzysztof Lewandowski, Barbara Zdziarska, Lech Konopka, Bernadetta Ceglarek, Jadwiga Dwilewicz-Trojaczek, Piotr Boguradzki, Kazimierz Kuliczkowski, Kazimierz Sułek, Krzysztof WarzochaMed Sci Monit 2005; 11(10): PI71-79 :: ID: 430316
Abstract
BACKGROUND: We previously published an early report of a randomized, multicentertrial on the efficacy and toxicity of cladribine (2-CdA) + prednisone (P) compared with chlorambucil(Chl) + P in previously untreated patients with progressive or symptomatic chronic lymphocytic leukemia.Here we present the final report of this study. MATERIAL/METHODS: Of 229 patients, 126 received 2-CdA+Pand 103 Chl+P. Patients with no response or progression after three courses or who relapsed earlier than12 months after completing one treatment were switched to the other. Patients who relapsed later wereretreated with the same schedule as before. RESULTS: Thirty-three patients were retreated with 2-CdA+Pand 19 with Chl+P. Overall response (and complete response) rates were 35% (6%) and 47% (16%), respectively.In 50 patients initially treated with Chl+P and then with 2-CdA+P, complete response (CR) was achievedin 12 (24%) and overall response (OR) in 32 (64%). In 28 patients originally treated with 2-CdA+P andthen with Chl+P, CR in 1 (3%, p=0.01) and OR in 6 (21%, p=0.003) were obtained. We found no statisticallysignificant difference in overall survival time in patients treated initially with 2-CdA+P and Chl+Paged 60 years (4.63 and 5.27 years, respectively, p=0.45), 60-70 years (3.29 and 3.14 years, p=0.79),and >70 years (1.53 and 1.93 years, p=0.11). CONCLUSIONS: 2-CdA+P is significantly more effective asa second-line treatment and re-treatment than Chl+P. However, we found a trend to longer survival inelderly patients treated with Chl+P.
Keywords: Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Chlorambucil - administration & dosage, Cladribine - administration & dosage, Cyclophosphamide - administration & dosage, Doxorubicin - administration & dosage, Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy, Prednisone - administration & dosage, Vincristine - administration & dosage
Editorial
01 October 2024 : Editorial
Editorial: Potentials and Pitfalls in Targeting Glucagon-Like Peptide-1 (GLP-1) in the Management of Increasing Levels of ObesityDOI: 10.12659/MSM.946675
Med Sci Monit 2024; 30:e946675
In Press
Clinical Research
Acupuncture Enhances Quality of Life and Disease Control in Chronic Spontaneous Urticaria Patients on Omali...Med Sci Monit In Press; DOI:
Review article
Sex and Population Variations in Nasopalatine Canal Dimensions: A CBCT-Based Systematic ReviewMed Sci Monit In Press; DOI:
Clinical Research
Cold Pressor Test Induces Significant Changes in Internal Jugular Vein Flow Dynamics in Healthy Young AdultsMed Sci Monit In Press; DOI: 10.12659/MSM.946055
Clinical Research
Serum Albumin-to-Creatinine Ratio Predicts One-Year Mortality in Elderly Patients with Non-ST-Elevation Acu...Med Sci Monit In Press; DOI: 10.12659/MSM.945516
Most Viewed Current Articles
17 Jan 2024 : Review article 6,057,747
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research 1,850,872
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research 694,012
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
07 Jan 2022 : Meta-Analysis 258,273
Efficacy and Safety of Light Therapy as a Home Treatment for Motor and Non-Motor Symptoms of Parkinson Dise...DOI :10.12659/MSM.935074
Med Sci Monit 2022; 28:e935074